Discovery of orally active anticancer candidate CFI-400945 derived from biologically promising spirooxindoles: Success and challenges

The ELISA assay of a focused kinase library yielded the indolinone as PLK4 inhibitor. Extensive modifications generated CFI-400945, which has entered phase I clinical trials for cancer therapy. However, the kinase selectivity is the major concern that needs to be further investigated.